Journal of Clinical Hepatology
This article studies the prevalence, influencing factors, and risk stratification of fibrosis in metabolic-related fatty liver disease (MAFLD) among Beijing's health check-up population. The study adopts an improved MAFLD diagnostic standard, combining imaging and metabolic risk factors to improve the accuracy of diagnosis. Through multifactorial logistic regression analysis, age, BMI, blood glucose, blood lipids, and other factors are identified as major risk factors, and patient characteristics and comorbidities are analyzed by BMI stratification, revealing the key role of obesity in the occurrence of MAFLD. The innovation lies in the application of non-invasive serum scoring systems such as FIB-4, NFS, APRI, and BARD for the risk stratification of MAFLD patients, with FIB-4 being recommended for initial screening due to its low cost and ease of access, making it suitable for large-scale population screening. The study also found that the prevalence of MAFLD is high and closely related to various metabolic abnormalities, indicating the need for early identification and stratified management. The results are of great significance for public health prevention and clinical practice.
The significance of this study lies in the systematic evaluation of the prevalence, influencing factors, and fibrosis risk stratification of metabolic-related fatty liver disease (MAFLD) among Beijing's health check-up population, providing a scientific basis for early screening and stratified management. With MAFLD replacing non-alcoholic fatty liver disease (NAFLD) as a new clinical concept, it is particularly important to clarify its epidemiological characteristics in the general population. Based on 3,125 health check-up data, the study adopts an improved MAFLD diagnostic standard, improves the accuracy of diagnosis, and identifies key risk factors through multifactorial logistic regression analysis, which helps in precise intervention for high-risk populations. In addition, the study uses non-invasive serum indicators such as FIB-4 to stratify the fibrosis risk of patients, finding that 15.4% of MAFLD patients have FIB-4≥1.3, some of whom require further liver hardness testing or specialized treatment, realizing a closed-loop management from screening to referral. This not only improves the efficiency of primary-level health management but also provides data support for formulating regional prevention and control strategies. The research achievements have important public health value in promoting the early prevention and treatment of MAFLD, reducing the progression of liver cirrhosis and liver cancer.
Objective: To identify the patients with metabolic dysfunction-associated fatty liver disease (MAFLD) among the health check-up...
